Progression of metabolic syndrome and associated cardiometabolic risk factors from prepuberty to puberty in children: The PUBMEP study
Metadata
Show full item recordAuthor
De Lamas, Carmela; Anguita Ruiz, Augusto; Gil Hernández, Ángel; Aguilera García, Concepción MaríaEditorial
Frontiers
Materia
Adolescent Cardiometabolic risk factor Child Metabolic syndrome Obesity Overweight Puberty
Date
2022-12-19Referencia bibliográfica
de Lamas C... [et al.] (2022) Progression of metabolic syndrome and associated cardiometabolic risk factors from prepuberty to puberty in children: The PUBMEP study. Front. Endocrinol. 13:1082684. doi: [10.3389/fendo.2022.1082684]
Sponsorship
Plan Nacional de Investigación Cientı́fica, Desarrollo e Innovación Tecnológica (I+D+I); Instituto de Salud Carlos III-Health Research Funding (FONDOS FEDER) (PI05/1968, PI11/01425, PI11/02042, PI11/ 02059, PI16/01301, PI16/01205, PI16/00871, PI20/00988, PI20/ 00924 and PI20/00563); CIBEROBN Network (CB15/00131, CB15/00043); Acción Estratégica en Salud 2013– 2016 (IFI17/00048); Research Plan of the Vice-Rectorate of Research and Transfer of the University of Granada, SpainAbstract
Introduction: Metabolic syndrome (MetS) is a cluster of clinical and metabolic
alterations related to the risk of cardiovascular diseases (CVD). Metabolic
changes occurring during puberty, especially in children with overweight and
obesity, can influence the risk of developing chronic diseases, especially CVD.
Methods: Longitudinal study based on the follow-up until puberty of a cohort
of 191 prepubertal Spanish boys and girls without congenital, chronic, or
inflammatory diseases: undernutrition: or intake of any drug that could alter
blood glucose, blood pressure, or lipid metabolism. The following parameters
were used to determine the presence of MetS: obesity, hypertension,
hyperglycemia, hypertriglyceridemia, and low HDL-c.
Results: A total of 75·5% of participants stayed in the same BMI category from
prepuberty to puberty, whereas 6·3% increased by at least one category. The
prevalence of MetS was 9·1% (prepubertal stage) and 11·9% (pubertal stage).
The risk of presenting alterations in puberty for systolic blood pressure (SBP),
plasma triacylglycerols, HDL cholesterol (HDL-c), and HOMA-IR was significantly higher in those participants who had the same alterations in
prepuberty. MetS prevalence in puberty was predicted by sex and levels of
HOMA-IR, BMI-z, and waist circumference in the prepubertal stage, in the
whole sample: in puberty, the predictors were levels of HOMA-IR, BMI-z, and
diastolic blood pressure in participants with obesity. Two fast-and-frugal
decision trees were built to predict the risk of MetS in puberty based on
prepuberty HOMA-IR (cutoff 2·5), SBP (cutoff 106 mm of Hg), and TAG (cutoff
53 mg/dl).
Discussion: Controlling obesity and cardiometabolic risk factors, especially
HOMA-IR and blood pressure, in children during the prepubertal stage appears
critical to preventing pubertal MetS effectively.